Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: What is the evidence?

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1413-1422

  Roger, S D ^a  

^a GOSFORD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AREA UNDER THE CURVE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

ANEMIA; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 49349114122     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01846.x     Document Type: Review

References (51)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987 316: 73 8.
2. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990 263: 825 30.
3. Bárány P, Petterson E, Konarski-Svensson JK. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 1993 8: 426 32.
4. Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000 11: 335 42.
5. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anaemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003 25: 1786 805.
6. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999 10: 610 9.
7. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anaemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002 40: 1153 61.
8. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006 17: 1181 91.
9. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999 10: 1309 16.
10. Dean BB, Dylan M, Gano A, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005 21: 981 7.
11. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007 50: 471 530.
12. Locatelli F, Aljama P, Bárány P et al., European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004 19 (Suppl. 2 ii1 47.
13. Barrett BJ, Fenton SS, Ferguson B et al. Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 1999 10 (Suppl. 13 S292 6.
14. Pollock C, McMahon L. Haemoglobin. Nephrology 2005 10 (Suppl. 4 S108 15.
15. Centers for Medicare & Medicaid Services. Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, 2004.
16. Locatelli F, Pisoni RL, Akizawa T et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004 44 (Suppl. 2 27 33.
17. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004 44: 94 111.
18. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005 20 (Suppl. 3 iii3 24.
19. US Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
20. Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991 50: 702 12.
21. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998 339: 578 83.
22. Vanrenterghem Y, Bárány P, Mann JF et al. European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002 62: 2167 75.
23. Hynes DM, Stroupe KT, Greer JW et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002 112: 169 75.
24. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999 10: 2392 5.
25. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006 45: 503 10.
26. Jarsch M, Brandt M, Lanzendörfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008 81: 63 9.
27. Macdougall IC, Robson R, Opatrna S et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006 1: 1211 5.
28. ® SPC (Summary of Product Characteristics). Available from: URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc. asp?DocumentID=19960 (Accessed June 2008).
29. Bernardo M, Crawford P, Hertel J et al. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting. J Manag Care Pharm 2006 12: 714 25.
30. Hoggard J, Crouch T, McMurray S et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 2006 22: 2023 30.
31. Mahon A, Docherty B. Renal anaemia - the patient experience. EDTNA/ERCA J 2004 30: 34 7.
32. Petroff S, Germain M, O'Shea M et al. Prolonged erythropoietin (EPO) dosing intervals in pre-ESRD patients. J Am Soc Nephrol 2001 12: 407A (Abstract A2098).
33. Piccoli A, Malagoli A, Komninos G, Pastori G. Subcutaneous epoetin-alpha therapy every one, two, and three weeks in renal anemia. J Nephrol 2002 15: 565 74.
34. Germain M, Ram CV, Bhaduri S, Tang KL, Klausner M, Curzi M. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Nephrol Dial Transplant 2005 20: 2146 52.
35. Grzeszczak W, Sulowicz W, Rutkowski B et al. European Collaborative Group. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005 20: 936 44.
36. Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005 64: 113 23.
37. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004 19: 898 903.
38. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005 63: 327 34.
39. Agarwal AK, Silver MR, Reed JE et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006 260: 577 85.
40. Disney A, Jersey PD, Kirkland G et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology 2007 12: 95 101.
41. Levin NW, Fishbane S, Valdés Cañedo F et al., on behalf of the MAXIMA study investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007 370: 1415 21.
42. Sulowicz W, Locatelli F, Ryckelynck J-P et al., on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007 2: 637 46.
43. Levin NW, Imbasciati E, Combe C et al. Adequate Hb levels are maintained with IV C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status. J Am Soc Nephrol 2006 17: 619A (Abstract SA-PO206).
44. Ryckelynck J-P, Harris K, Selgas R et al. SC C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. J Am Soc Nephrol 2006 17: 620A (Abstract SA-PO210).
45. Provenzano R, Singh AK. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract 2007 13: 251 9.
46. Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc 2007 8: 83 90.
47. Roger SD, Cooper B. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Nephrology 2004 9: 223 8.
48. Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006 22: 837 42.
49. Fishbane S. Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006 19: 1 4.
50. Rice L, Alfrey CP. The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 2005 15: 245 50.
51. Gilbertson D, Ebben J, Collins A. The effect of hemoglobin variability on hospitalization and mortality. Nephrol Dial Transplant 2006 21 (Suppl. 4 iv169 (Abstract SP458).